Clinuvel Pharmaceuticals Management
Management criteria checks 2/4
Clinuvel Pharmaceuticals' CEO is Philippe Wolgen, appointed in Nov 2005, has a tenure of 19.08 years. total yearly compensation is A$3.74M, comprised of 47.2% salary and 52.8% bonuses, including company stock and options. directly owns 6.86% of the company’s shares, worth A$40.38M. The average tenure of the management team and the board of directors is 1 years and 5.1 years respectively.
Key information
Philippe Wolgen
Chief executive officer
AU$3.7m
Total compensation
| CEO salary percentage | 47.2% |
| CEO tenure | 19.1yrs |
| CEO ownership | 6.9% |
| Management average tenure | less than a year |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$4m | AU$2m | AU$36m |
| Mar 31 2024 | n/a | n/a | AU$33m |
| Dec 31 2023 | n/a | n/a | AU$30m |
| Sep 30 2023 | n/a | n/a | AU$30m |
| Jun 30 2023 | AU$6m | AU$2m | AU$31m |
| Mar 31 2023 | n/a | n/a | AU$29m |
| Dec 31 2022 | n/a | n/a | AU$26m |
| Sep 30 2022 | n/a | n/a | AU$24m |
| Jun 30 2022 | AU$7m | AU$1m | AU$21m |
| Mar 31 2022 | n/a | n/a | AU$22m |
| Dec 31 2021 | n/a | n/a | AU$24m |
| Sep 30 2021 | n/a | n/a | AU$24m |
| Jun 30 2021 | AU$5m | AU$2m | AU$25m |
| Mar 31 2021 | n/a | n/a | AU$23m |
| Dec 31 2020 | n/a | n/a | AU$21m |
| Sep 30 2020 | n/a | n/a | AU$18m |
| Jun 30 2020 | AU$3m | AU$2m | AU$15m |
| Mar 31 2020 | n/a | n/a | AU$15m |
| Dec 31 2019 | n/a | n/a | AU$15m |
| Sep 30 2019 | n/a | n/a | AU$16m |
| Jun 30 2019 | AU$1m | AU$894k | AU$18m |
| Mar 31 2019 | n/a | n/a | AU$17m |
| Dec 31 2018 | n/a | n/a | AU$16m |
| Sep 30 2018 | n/a | n/a | AU$15m |
| Jun 30 2018 | AU$2m | AU$818k | AU$13m |
Compensation vs Market: Philippe's total compensation ($USD2.34M) is above average for companies of similar size in the Australian market ($USD888.46K).
Compensation vs Earnings: Philippe's compensation has been consistent with company performance over the past year.
CEO
Philippe Wolgen (61 yo)
19.1yrs
Tenure
AU$3,742,412
Compensation
Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 19.1yrs | AU$3.74m | 6.86% A$ 40.4m | |
| Chief Scientific Officer | 12.3yrs | AU$782.61k | 0.38% A$ 2.2m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operations Officer | no data | no data | no data | |
| Head of Australian Operations & Investor Relations | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | no data | |
| Head of Quality Assurance & Drug Safety | less than a year | no data | no data | |
| Company Secretary | less than a year | no data | no data |
1.0yrs
Average Tenure
Experienced Management: CUV's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 19.2yrs | AU$3.74m | 6.86% A$ 40.4m | |
| Non-Executive Director | less than a year | no data | no data | |
| Non-Executive Director | less than a year | no data | no data | |
| Non-Executive Director | 5.3yrs | AU$80.00k | 0.00084% A$ 4.9k | |
| Non-Executive Chairman | 5.1yrs | AU$91.67k | 0.0063% A$ 37.1k | |
| Non-Executive Director | 6.9yrs | AU$75.00k | 0.028% A$ 163.1k | |
| Non-Executive Director | less than a year | no data | no data |
5.1yrs
Average Tenure
Experienced Board: CUV's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 22:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clinuvel Pharmaceuticals Limited is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Wakim | Bell Potter |
| Norbert Kalliwoda | Dr. Kalliwoda Research |
| David Stanton | Jefferies LLC |